血清CEA及CA153连续且显著降低对晚期乳腺癌无影像学进展的判定价值

Predictive value of continuous and significant reduction of serum CEA and CA153 for non-imaging progression in patients with advanced breast cancer

目的:探讨晚期乳腺癌患者化疗后血清CEA及CA153连续且显著降低对无影像学进展的判定价值。方法:回顾性分析2011年1月至2015年12月93例沈阳军区总医院住院化疗的晚期乳腺癌患者的病历资料,实施疗效评价188次,有完整CEA、CA153数据的病例分别为105、139例次,分析血清CEA及CA153连续且显著降低对于疾病无影像学进展的判定效度。结果:CEA连续降低且降低总幅度达10%时,敏感度为54.1%,特异度为95%;CA153连续降低且降低总幅度达40%时,敏感度为19.1%,特异度为96.6%。结论:血清CEA及CA153连续降低分别达10%与40%以上时可作为晚期乳腺癌患者的疗效判定指标。

Objective：This study evaluates the relationship between carcino-embryonic antigen （CEA） and carbohydrate antigen 153 （CA153） continuous and remarkable reduction after chemotherapy and no-imaging progression in patients with advanced breast can-cer. Methods： Medical records of 93 patients who received chemotherapy in the Oncology Department of the General Hospital of Shenyang Military Command were included in the retrospective analysis. A total of 188 CEA and CA153 serum data were collected from response evaluations that included 105 CEA cases and 139 CA153 cases. Predictive validity of serum CEA and CA153 was as-sessed for diagnosing no-imaging progression. Results：CEA was continuously reduced by 10%, with sensitivity of 54.1%and specificity of 95%. CA153 was continuously reduced by 40%, with sensitivity of 19.1%and specificity of 96.6%. Conclusion：Serum CEA and CA153 could be considered as response evaluation tools when they are continuously reduced by at least 10%and 40%, respectively.